Regina M. Paglia Net Worth

The estimated Net Worth of Regina M. Paglia is at least 289 千$ dollars as of 6 July 2021. Regina Paglia owns over 3,162 units of Dicerna Pharmaceuticals Inc stock worth over 131,133$ and over the last 4 years Regina sold DRNA stock worth over 158,150$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Regina Paglia DRNA stock SEC Form 4 insiders trading

Regina has made over 13 trades of the Dicerna Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Regina exercised 3,162 units of DRNA stock worth 120,852$ on 6 July 2021.

The largest trade Regina's ever made was exercising 31,945 units of Dicerna Pharmaceuticals Inc stock on 15 June 2021 worth over 526,134$. On average, Regina trades about 8,899 units every 17 days since 2020. As of 6 July 2021 Regina still owns at least 3,431 units of Dicerna Pharmaceuticals Inc stock.

You can see the complete history of Regina Paglia stock trades at the bottom of the page.

What's Regina Paglia's mailing address?

Regina's mailing address filed with the SEC is C/O DICERNA PHARMACEUTICALS, INC., 75 HAYDEN AVENUE, LEXINGTON, MA, 02421.

Insiders trading at Dicerna Pharmaceuticals Inc

Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over 233,644,011$ worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth 36,501,331$ . The most active insiders traders include Capital Management, Llc Kol...、Nicole Vitullo、Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,025,674$. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth 78,351$.

What does Dicerna Pharmaceuticals Inc do?

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.

Complete history of Regina Paglia stock trades at Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc executives and stock owners

Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Douglas Fambrough,
  President, Chief Executive Officer, Director
• Robert Ciappenelli,
  Chief Commercial Officer
• Bob Brown,
  Executive Vice President, Research and Development, Chief Scientific Officer
• James Weissman,
  Chief Operating Officer, Executive Vice President
• J. Kevin Buchi,
  Independent Chairman of the Board
• Marc Kozin,
  Independent Director
• Anna Protopapas,
  Independent Director
• Adam Koppel,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Martin Freed,
  Independent Director
• Cynthia Smith,
  Independent Director
• Patrick Gray,
  Independent Director
• Ling Zeng,
  Chief Legal Officer and Secretary
• Shreeram Aradhye,
  Executive Vice President, Chief Medical Officer
• Douglas Pagan,
  Chief Financial Officer
• Stephen Doberstein,
  Independent Director
• Capital Management, Llc Kol...,
  
• Partners Viii, L.P.Blair Ja...,
  
• Theodore Ashburn,
  See Remarks
• John B Green,
  Chief Financial Officer
• David Madden,
  Director
• Pankaj Bhargava,
  Chief Medical Officer
• Viii Associates, L.P.Blair ...,
  
• Bruce Peacock,
  Director
• Ralf Rosskamp,
  Chief Medical Officer
• Brian K Halak,
  Director
• Regina M. Paglia,
  Chief Human Resources Officer
• Capital Life Sciences Inves...,
  
• Capital Management, Llcra C...,
  
• Peter Kolchinsky,
  Director
• Bart W Wise,
  SVP, Legal Affairs
• Dennis Langer,
  Director
• James C Blair,
  10% owner
• Venture Partners V Lp Skyli...,
  
• James E Dentzer,
  Chief Financial Officer
• James E Deerfield Mgmt L.P....,
  
• James E Deerfield Mgmt L.P....,
  
• Vincent J Miles,
  Director
• Capital Management Llcbrook...,
  
• Kathleen K Schoemaker,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Nicole Vitullo,
  10% owner
• Brian H Dovey,
  10% owner
• Jesse I Treu,
  10% owner
• Viii Associates, L.P. Dp,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner